

Guideline Page and Request	Panel Discussion/References	Institution Vote			
		YES	NO	ABSTAIN	ABSENT
<b>HCC-5 and HCC-6</b> <u>Internal request:</u> Institutional review comment to consider the inclusion of nivolumab as a treatment option for hepatocellular carcinoma (HCC). <u>External request:</u> Submission request from Bristol-Myers Squibb Co. to review clinical data that has been published in the Lancet on CheckMate 040, a phase 1/2 dose escalation and expansion trial that evaluated the safety and efficacy of nivolumab monotherapy for the treatment of patients with advanced HCC not amenable to curative resection.	<p>Based upon review of the data and FDA approval, the panel consensus was to add nivolumab for patients with unresectable hepatocellular carcinoma cancer (HCC) who are not candidates for transplant; patients with disease that is inoperable by performance status or comorbidity, local disease or local disease with minimal extrahepatic disease only; and patients with metastatic disease or extensive liver tumor burden (Child-Pugh Class A or B7 liver function only). This is a category 2A recommendation.</p> <ul style="list-style-type: none"> <li>El-Khoueiry A, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 2017;389:2492-2502.</li> </ul>	16	0	0	12

